Rx Product News

Pharmacy TimesMay 2014 Skin & Eye Health
Volume 80
Issue 5

Our round-up of new Rx products.

Marketed by: Alcon Laboratories, Inc

Indication: The screw-top cap of Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension 1%/0.2%) has been changed from white to light green to help patients distinguish the medication from other glaucoma treatments. Simbrinza is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The medication should be shaken well before use, and 1 drop should be instilled in the affected eye(s) 3 times daily.

Dosage Form: Suspension: brinzolamide 10 mg/mL, brimonidine tartrate 2 mg/mL

For More Information: www.myglaucomasupport.com/

Marketed by: Cornerstone Therapeutics Inc

Indication: The FDA has approved Bethkis (tobramycin inhalation solution), an inhaled aminoglycoside antibacterial, for the management of cystic fibrosis patients with Pseudomonas aeruginosa infection. The entire contents of 1 ampule should be administered twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. Bethkis is formulated as a clear, colorless to pale yellow solution for oral inhalation.

Dosage Form: Single-use ampule: 300 mg

For More Information: http://bethkis.com

Janssen Therapeutics

Indication: The FDA has approved Olysio (simeprevir; a hepatitis C virus NS3/4A protease inhibitor) for the treatment of chronic hepatitis C infection, as a component of a combination antiviral treatment regimen. The recommended dosage is one 150-mg capsule taken once daily with food. Olysio should be administered with peginterferon alfa and with ribavirin for 12 weeks, followed by either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on prior response status.

Dosage Form: Capsules: 150 mg

For More Information: www.olysio.com

NoxafilMarketed by: Merck & Co, Inc

Indication: The FDA has approved Noxafil injection (posaconazole) for intravenous (IV) use. It is indicated for prophylaxis against invasive Aspergillus and Candida infections in severely immunocompromised patients. The recommended dosage is a loading dose of 300 mg IV twice a day on the first day, followed by 300 mg IV once a day. Noxafil injection must be administered through an inline filter by IV infusion over ~90 minutes via a central venous line. It should never be given as an IV bolus injection.

Dosage Form: Injection: 18 mg/mL

For More Information: www.noxafil.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.